Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...
Joe Jimenez's Aditum Bio, an investment firm that builds companies around in-licensed assets, is going after one of the hottest new areas for its latest startup. The Oakland, CA-based firm ...
Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction ...
Sarepta Therapeutics is stopping development of vesleteplirsen, an experimental exon 51-skipping therapy for Duchenne muscular dystrophy patients with certain mutations. It's also halting work on all ...
California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...
In his first quarter leading CVS Health, CEO David Joyner laid out the initial steps he’s taking to rightsize the company, as ...
Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its decision to take the … ...
US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential ...
Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker ...
As former President Donald Trump returns to power — the Associated Press projected his presidential victory Wednesday morning — the biopharma industry may see the door open wider for more dealmaking, ...
Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback